EP1140066A4 - Composes et compositions antagonistes de recepteurs de h 2? nitroses et nitrosyles et procedes d'utilisation - Google Patents

Composes et compositions antagonistes de recepteurs de h 2? nitroses et nitrosyles et procedes d'utilisation

Info

Publication number
EP1140066A4
EP1140066A4 EP99962784A EP99962784A EP1140066A4 EP 1140066 A4 EP1140066 A4 EP 1140066A4 EP 99962784 A EP99962784 A EP 99962784A EP 99962784 A EP99962784 A EP 99962784A EP 1140066 A4 EP1140066 A4 EP 1140066A4
Authority
EP
European Patent Office
Prior art keywords
nitrosylated
nitrosated
compositions
methods
receptor antagonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99962784A
Other languages
German (de)
English (en)
Other versions
EP1140066A1 (fr
Inventor
David S Garvey
L Gordon Letts
Tiansheng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nitromed Inc
Original Assignee
Nitromed Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nitromed Inc filed Critical Nitromed Inc
Publication of EP1140066A1 publication Critical patent/EP1140066A1/fr
Publication of EP1140066A4 publication Critical patent/EP1140066A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/092—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings with aromatic radicals attached to the chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Furan Compounds (AREA)
EP99962784A 1998-11-17 1999-11-17 Composes et compositions antagonistes de recepteurs de h 2? nitroses et nitrosyles et procedes d'utilisation Withdrawn EP1140066A4 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10887798P 1998-11-17 1998-11-17
US108877P 1998-11-17
US14083999P 1999-06-28 1999-06-28
US140839P 1999-06-28
PCT/US1999/027207 WO2000028988A1 (fr) 1998-11-17 1999-11-17 Composes et compositions antagonistes de recepteurs de h2 nitroses et nitrosyles et procedes d'utilisation

Publications (2)

Publication Number Publication Date
EP1140066A1 EP1140066A1 (fr) 2001-10-10
EP1140066A4 true EP1140066A4 (fr) 2005-11-09

Family

ID=26806378

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99962784A Withdrawn EP1140066A4 (fr) 1998-11-17 1999-11-17 Composes et compositions antagonistes de recepteurs de h 2? nitroses et nitrosyles et procedes d'utilisation

Country Status (6)

Country Link
US (4) US6552047B2 (fr)
EP (1) EP1140066A4 (fr)
JP (1) JP2002529503A (fr)
AU (1) AU772188B2 (fr)
CA (1) CA2349575A1 (fr)
WO (1) WO2000028988A1 (fr)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7141244B1 (en) * 1992-03-02 2006-11-28 Chiron Srl Helicobacter pylori proteins useful for vaccines and diagnostics
GB2303855B (en) * 1994-07-01 1998-10-28 Rican Limited Helicobacter pylori antigenic protein preparation and immunoassays
ATE355375T1 (de) * 1996-01-04 2006-03-15 Novartis Vaccines & Diagnostic Bakterioferritin aus helicobacter pylori
US7846180B2 (en) 1999-06-22 2010-12-07 Ethicon Endo-Surgery, Inc. Tissue fixation devices and methods of fixing tissue
US8287554B2 (en) * 1999-06-22 2012-10-16 Ethicon Endo-Surgery, Inc. Method and devices for tissue reconfiguration
US6821285B2 (en) 1999-06-22 2004-11-23 Ndo Surgical, Inc. Tissue reconfiguration
US6835200B2 (en) 1999-06-22 2004-12-28 Ndo Surgical. Inc. Method and devices for tissue reconfiguration
US6663639B1 (en) * 1999-06-22 2003-12-16 Ndo Surgical, Inc. Methods and devices for tissue reconfiguration
CA2458854A1 (fr) * 2001-08-31 2003-03-06 Chiron Srl Vaccination contre helicobacter pylori avec une combinaison de proteinescaga, vaca et nap
AU2006252204B2 (en) * 2001-12-06 2010-07-08 Duke University Prevention of Flap Necrosis in Plastic Surgery
US20030203915A1 (en) * 2002-04-05 2003-10-30 Xinqin Fang Nitric oxide donors, compositions and methods of use related applications
US20040038947A1 (en) 2002-06-14 2004-02-26 The Gov. Of The U.S. Of America As Represented By The Sec. Of The Dept. Of Health & Human Services Method of treating ischemia/reperfusion injury with nitroxyl donors
US6936639B2 (en) 2002-08-21 2005-08-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Nitroxyl progenitors in the treatment of heart failure
WO2005023189A2 (fr) * 2003-09-03 2005-03-17 Pharmacia Corporation Procede de prevention ou de traitement de la douleur, de l'inflammation, et de troubles lies a l'inflammation avec un inhibiteur selectif de cox-2 en combinaison avec un agent donneur de monoxyde d'azote et compositions en contenant
US8134010B2 (en) * 2004-05-05 2012-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having aryl substituent(s) and uses thereof
WO2005105765A1 (fr) * 2004-05-05 2005-11-10 Renopharm Ltd. Donneurs d'oxyde nitrique et utilisations de ceux-ci
US7968575B2 (en) * 2004-05-05 2011-06-28 Renopharm Ltd. Nitric oxide donors and uses thereof
EP1814535A4 (fr) * 2004-11-08 2008-06-04 Nitromed Inc Composes nitroses et nitrosyles, compositions et procedes destines au traitement de troubles ophtalmiques
JP2008520578A (ja) * 2004-11-15 2008-06-19 ニトロメッド インコーポレーティッド 複素環式の酸化窒素供与体基を含む利尿化合物、組成物および使用方法
US20090042819A1 (en) * 2005-02-16 2009-02-12 Nitromed, Inc. Organic nitric oxide donor salts of antimicrobial compounds, compositions and methods of use
US20080020040A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Unit dose form for administration of ibuprofen
JP2009501801A (ja) * 2005-07-18 2009-01-22 ホライゾン セラピューティクス， インコーポレイテッド イブプロフェンとファモチジンとを含有する医薬およびその投与
US20080021078A1 (en) * 2006-07-18 2008-01-24 Horizon Therapeutics, Inc. Methods and medicaments for administration of ibuprofen
US8067451B2 (en) 2006-07-18 2011-11-29 Horizon Pharma Usa, Inc. Methods and medicaments for administration of ibuprofen
US20090018091A1 (en) 2005-08-02 2009-01-15 Nitromed, Inc. Nitric Oxide Enhancing Antimicrobial Compounds, Compositions and Methods of Use
AU2007243765A1 (en) 2006-03-29 2007-11-08 Nicox S.A. Nitric oxide enhancing prostaglandin compounds, compositions and methods of use
US8067033B2 (en) 2007-11-30 2011-11-29 Horizon Pharma Usa, Inc. Stable compositions of famotidine and ibuprofen
WO2008027963A2 (fr) * 2006-08-31 2008-03-06 Horizon Therapeutics, Inc. Formulations à dose unique d'ains avec antagonistes du récepteur de h2, et procédés d'utilisation
US7801502B2 (en) * 2006-12-18 2010-09-21 Aai Corporation Method for implementing continuous radio frequency (RF) alignment in advanced electronic warfare (EW) signal stimulation systems
US8852216B2 (en) 2007-03-23 2014-10-07 Ethicon Endo-Surgery, Inc. Tissue approximation methods
US8771643B2 (en) 2008-01-04 2014-07-08 Schabar Research Associates Llc Use of analgesic potentiating compounds to potentiate the analgesic properties of an analgesic compound
US8058296B2 (en) * 2008-11-25 2011-11-15 Richard Tokunaga Treatment and prevention of deleterious effects associated with alcohol consumption
US9018411B2 (en) 2009-12-07 2015-04-28 Cardioxyl Pharmaceuticals, Inc. Bis-acylated hydroxylamine derivatives
US8409628B2 (en) 2010-02-04 2013-04-02 Penguin IP Holdings, Inc. Methods and compositions for oxygenation of skin to treat skin disorders
WO2011123619A2 (fr) 2010-03-31 2011-10-06 Penguin Ip Holdings Inc. Mélanges perméables, procédés et compositions pour la peau
WO2015009882A2 (fr) * 2013-07-18 2015-01-22 The Hamner Institutes Dérivés cyano et leurs utilisations
US11331307B2 (en) 2020-07-15 2022-05-17 Schabar Research Associates, Llc Unit oral dose compositions composed of ibuprofen and famotidine for the treatment of acute pain and the reduction of the severity and/or risk of heartburn
US11324727B2 (en) 2020-07-15 2022-05-10 Schabar Research Associates, Llc Unit oral dose compositions composed of naproxen sodium and famotidine for the treatment of acute pain and the reduction of the severity of heartburn and/or the risk of heartburn

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54106468A (en) * 1978-02-10 1979-08-21 Mitsubishi Yuka Yakuhin Kk Imidazole derivative and its manufacture
DE2946332A1 (de) * 1978-11-16 1980-05-29 Glaxo Group Ltd Alpha , omega -disubstituierte polymethylenverbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0164040A2 (fr) * 1984-06-06 1985-12-11 AUSONIA FARMACEUTICI S.r.l. Dérivés de furane à activité anti-ulcères
US5037815A (en) * 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US5102902A (en) * 1973-06-18 1992-04-07 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
US5403830A (en) * 1987-03-09 1995-04-04 The Proctor & Gamble Company Compositions and methods of treating gastrointestinal disorders
US5541212A (en) * 1994-01-10 1996-07-30 Metatron, Inc. Use of cimetidine for the control of retrovirus infections
US5656652A (en) * 1991-12-20 1997-08-12 Smithkline Beecham Plc Compositions containing histamine-H2 -receptor antagonists at low dosage
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338169A (en) 1971-03-09 1973-11-21 Smith Kline French Lab Ureas thioureas and guanidines
US4279906A (en) 1977-11-10 1981-07-21 Nasa Indomethacin-antihistamine combination for gastric ulceration control
JPS6056143B2 (ja) * 1979-08-02 1985-12-09 山之内製薬株式会社 アミジン誘導体ならびにその製造法
US4293557A (en) * 1979-07-03 1981-10-06 Teikoku Hormone Mfg. Co., Ltd. Antiulcer phenoxypropylamine derivatives
US4375547A (en) 1980-10-02 1983-03-01 Eli Lilly And Company N-Methyl-N'-2-([(2-dimethylaminomethyl)-4-thiazolyl]methylthio)ethyl 2-nitro-1,1-ethenediamine
CA1254212A (fr) * 1982-11-12 1989-05-16 Shiro Hirai Amines derives, leur sels, procede de preparation et agent anti-ulcereux les contenant
US4742083A (en) 1983-08-24 1988-05-03 Lever Brothers Company Method of relieving pain and inflammatory conditions employing substituted salicylamides
NZ215069A (en) 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
HU194845B (en) * 1985-09-11 1988-03-28 Richter Gedeon Vegyeszet Process for production of n-sulphamil-3-/2-guanidintiazolil-4-methil-tio/-propion-amidin
EP0224612A1 (fr) 1985-12-05 1987-06-10 HEUMANN PHARMA GMBH & CO Procédé de préparation de N-cyano-N'-méthyl-N''[(méthyl-5-imidazolyl-4)méthylthio)-2-éthyl]guanidine
IL85472A (en) 1987-03-09 1991-06-30 Procter & Gamble Pharmaceutical compositions for treating gastrointestinal disorders
EP0285681B1 (fr) 1987-04-06 1993-03-10 HEUMANN PHARMA GMBH & CO Procédé pour la préparation de dérivés de nitroéthène
KR960011236B1 (ko) 1987-05-08 1996-08-21 스미스 클라인 앤드 프렌취 라보라토리스 리미티드 제약학적 조성물 및 고체 제형
US5196205A (en) 1987-10-12 1993-03-23 Borody Thomas J Method for treatment of gastro intestinal disorders
US4900741A (en) 1988-06-30 1990-02-13 Biomed Researchy Consultants, Ltd. Combined cimetidine-pirensepine formulation for treating peptic ulcers and erosions
CS274996B2 (en) 1989-05-24 1991-12-17 Ustav Ex Farmakol Drugs for stomach and duodenum ulcerous disease
FR2655266B1 (fr) 1989-12-05 1992-04-03 Smith Kline French Lab Compositions pharmaceutiques a base de cimetidine.
WO1994007541A1 (fr) 1992-09-29 1994-04-14 Merck & Co., Inc. Combinaisons d'ibuprofene-antihistaminique anti-h¿2?
WO1995010281A1 (fr) 1993-10-13 1995-04-20 Merck & Co., Inc. Traitement associe pour l'infection par le vih
CA2176414A1 (fr) 1995-05-18 1996-11-19 S. David Kimball Promedicaments a base de guanidine et d'amidine acylees
SE9600791L (sv) 1996-02-27 1997-08-28 Holdingbolaget Vid Goeteborgs Metod för eradikering av Helicobacter pylori infektion
WO1997033576A1 (fr) 1996-03-12 1997-09-18 Bristol-Myers Squibb Company Bioprecurseurs de carbamyl guanidine et d'amidine
IT1298338B1 (it) 1998-03-05 1999-12-20 Nicox Sa Composizioni farmaceutiche per l'ulcera
IT1299198B1 (it) 1998-03-05 2000-02-29 Nicox Sa Sali nitrati di farmaci antiulcera
US7189750B2 (en) * 2004-05-05 2007-03-13 Renopharm Ltd. Thiazole-based nitric oxide donors having at least two thiazole moieties and uses thereof

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5102902A (en) * 1973-06-18 1992-04-07 Mercer James B Reagents and method for therapeutic treatment of multiple sclerosis
JPS54106468A (en) * 1978-02-10 1979-08-21 Mitsubishi Yuka Yakuhin Kk Imidazole derivative and its manufacture
DE2946332A1 (de) * 1978-11-16 1980-05-29 Glaxo Group Ltd Alpha , omega -disubstituierte polymethylenverbindungen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
EP0164040A2 (fr) * 1984-06-06 1985-12-11 AUSONIA FARMACEUTICI S.r.l. Dérivés de furane à activité anti-ulcères
US5037815A (en) * 1986-03-04 1991-08-06 Bristol-Myers Squibb Co. Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers
US5403830A (en) * 1987-03-09 1995-04-04 The Proctor & Gamble Company Compositions and methods of treating gastrointestinal disorders
US5656652A (en) * 1991-12-20 1997-08-12 Smithkline Beecham Plc Compositions containing histamine-H2 -receptor antagonists at low dosage
US5541212A (en) * 1994-01-10 1996-07-30 Metatron, Inc. Use of cimetidine for the control of retrovirus infections
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
DATABASE HCAPLUS STN; 12 May 1984 (1984-05-12), XP002329203, retrieved from STN Database accession no. 92:58780/DN *
DATABASE HCAPLUS STN; 18 March 1998 (1998-03-18), XP002329205, retrieved from STN Database accession no. 128:226033/DN *
FOYE, WILLIAM O., LEMKE, THOMAS L., WILLIAMS, DAVID A.: "Principles of Medicinal Chemistry (4th Ed.)", 1995, WILLIAMS & WILKINS, BALTIMORE, XP002329202 *
MONTZKA T A ET AL: "COMPARATIVE NITROSATION OF ETINTIDINE AND CIMETIDINE", CANADIAN JOURNAL OF CHEMISTRY, NATIONAL RESEARCH COUNCIL. OTTAWA, CA, vol. 61, 1983, pages 1771 - 1777, XP008042601, ISSN: 0008-4042 *
SHIBATA, H. ET AL., YAKUGAKU ZASSHI, vol. 118, no. 3, 1998, pages 88 - 104 *
SORBA G ET AL: "MIXED ANTISECRETORY AND GASTROPROTECTIVE ACTIVITIES OF A NEW H2-ANTAGONIST CONTAINING A NITRIC OXIDE-DONOR FUROXAN MOIETY", ARZNEIMITTEL FORSCHUNG. DRUG RESEARCH, EDITIO CANTOR VERLAG, AULENDORF, DE, vol. 47, no. 7, 1997, pages 849 - 854, XP008042766, ISSN: 0004-4172 *

Also Published As

Publication number Publication date
US20070004788A1 (en) 2007-01-04
AU1915200A (en) 2000-06-05
US7129251B2 (en) 2006-10-31
US20020077343A1 (en) 2002-06-20
US6552047B2 (en) 2003-04-22
WO2000028988A1 (fr) 2000-05-25
US7256205B2 (en) 2007-08-14
CA2349575A1 (fr) 2000-05-25
US20030060492A1 (en) 2003-03-27
AU772188B2 (en) 2004-04-08
US6936627B2 (en) 2005-08-30
US20050250758A1 (en) 2005-11-10
EP1140066A1 (fr) 2001-10-10
JP2002529503A (ja) 2002-09-10

Similar Documents

Publication Publication Date Title
EP1140066A4 (fr) Composes et compositions antagonistes de recepteurs de h 2? nitroses et nitrosyles et procedes d'utilisation
EP1109542A4 (fr) Antagonistes nitroses et nitrosyles des recepteurs alpha-adrenergiques, compositions et methodes d'utilisation
IL150368A0 (en) Nitrosated and nitrosylated cyclooxygenase-2-inhibitors, compositions and methods of use
EP1109543A4 (fr) Inhibiteurs de la phosphodiesterase nitroses et nitrosyles, compositions et methodes d'utilisation
HK1051383A1 (zh) 突變的bmp1b受體做為排卵率的調節劑
AU5265599A (en) Amine compounds, their production and their use as somatostatin receptor antagonists or agonists
PL365684A1 (en) N-oxides as nk1 receptor antagonist prodrugs of 4-phenyl-pyridine derivatives
GB2343891B (en) 4-Aroyl-piperidine CCR-3 receptor antagonists
GB9927228D0 (en) CCR-3 receptor antagonists II
IL158701A0 (en) Novel use of nk3 receptor antagonist
PL342692A1 (en) Derivatives of 2-arylethyl-(piperidin-4-ylmethyl)amine as antagonists of muscarinic receptor
ZA9895B (en) Substituted bis-acridines and related compounds as ccr5 receptor antagonists antiinflammatory agents and antiviral agents
PL340282A1 (en) Novel derivatives of cyclopentene useful as antagonists of motilin receptor
AU1667500A (en) N-(2-phenyl-4-piperidinybutyl)-5,6,7,8-tetrahydro-1-naphthal necarboxamides and their use as neurokinin 1 (nk1) and/or neurokinin 2 (nk2) receptor antagonists
PL335100A1 (en) Oxazolynones as antagonists of 5ht2a receptor
PL350536A1 (en) Biphenyl derivatives as antagonists of the neurokinine-1 receptor
EG24025A (en) Vitronectin receptor antagonist
PL338453A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
HUP9903480A2 (en) Indoline derivatives useful as 5-ht-2c receptor antagonists
PL330796A1 (en) Derivatives of indolin useful as antagonists of 5-ht-2c receptor
PL337713A1 (en) Quaternary ammonia compounds as antagonists of tachykinins
EP1120426A4 (fr) Nouveaux recepteurs couples a la proteine g
PL338456A1 (en) 2-acylaminopropanoamines as antagonists of the tachykinin receptor
EP1131335A4 (fr) Hlwar77 du recepteur de 7tm
ZA981206B (en) Use of NMDA receptor antagonist

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010611

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20050920

17Q First examination report despatched

Effective date: 20060508

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20080812